Genitourinary Muscle Invasive Urothelial Cancer

Non-Muscle Invasive
- Prior Surgery
- No Prior BCG

Muscle Invasive
- Neoadjuvant
- Cisplatin Ineligible
- Adjuvant

Metastatic
- FGF/FGFR Alteration Positive

First Line Treatment
- Rare

CROSS-DISEASE TRIALS
- IRB# 19408 KEYNOTE-676: Phase 3 of Pembrolizumab in Combination with Bacillus Calmette-Guerin (BCG) in Participants with Non-Muscle Invasive Bladder Cancer
- IRB# 17381 S1602: A Phase III Randomized Trial for BCG- Naive High-Grade Non-Muscle Invasive Bladder Cancer
- IRB# 19301 PrECOG Ph 1b Neoadjuvant Nivolumab / Lirilumab
- IRB# 19259 Hoosier Onc Neoadjuvant gem/cis + Nivo
- IRB# 20103 A Phase 2, Open-Label, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of NKTR-214 in Combination with Nivolumab in Cisplatin Ineligible, Locally Advanced or Metastatic Urothelial Cancer Patients
- IRB# 20050 A Phase 2, Study of NKTR-214 in Combination with Nivolumab in Cisplatin Ineligible, Locally Advanced or Metastatic Urothelial Cancer Patients
- IRB# 20229 A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers

Key:
- Open for Enrollment
- In Development
- Enrollment on Hold

http://www.ohsu.edu/research/rda/so/knight.php
IRB# TBD
A PROSPECTIVE OBSERVATIONAL COHORT STUDY TO ASSESS miRNA 371 FOR OUTCOME PREDICTION IN PATIENTS WITH NEWLY DIAGNOSED GERM CELL TUMORS